コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 eeks) or placebo; all patients also received best supportive care.
2 y to patients previously only considered for best supportive care.
3 ne marrow fibrosis, or improve survival over best supportive care.
4 g per day) or placebo; all patients received best supportive care.
5 d radiotherapy alone, temozolomide alone, or best supportive care.
6 ebo (203 patients), both in conjunction with best supportive care.
7 appropriate need for systemic therapy versus best supportive care.
8 272) or placebo (n=138), in conjunction with best supportive care.
9 ther gefitinib (250 mg/day) or placebo, plus best supportive care.
10 trials comparing cytotoxic chemotherapy with best supportive care.
11 of $64,401 per life-year gained, compared to best supportive care.
12 $87,502 per life-year gained, compared with best supportive care.
13 antly improve overall survival compared with best supportive care.
14 199 assigned to rigosertib, 100 assigned to best supportive care.
17 ab plus best supportive care was superior to best supportive care alone for patients with symptomatic
19 icant survival benefit for chemotherapy over best supportive care and gemcitabine combinations over g
20 parallel groups to receive either CPAP with best supportive care (BSC) or BSC alone for 12 months.
24 xamined were as follows: chemotherapy versus best supportive care; fluorouracil (FU) versus FU combin
25 to three referral centers who were receiving best supportive care following permanent discontinuation
26 tudy comparing HLA-identical sibling HSCT to best supportive care for children with less severe SCD.
28 2) stratified by IPSS risk was compared with best supportive care for patients with nonanemic low/int
29 sertib group and 5.9 months (4.1-9.3) in the best supportive care group (hazard ratio 0.87, 95% CI 0.
30 tib group and 30 (33%) of 91 patients in the best supportive care group died due to adverse events an
31 ib group vs seven [8%] of 91 patients in the best supportive care group), thrombocytopenia (35 [19%]
34 Chemotherapy improved survival compared with best supportive care (hazard ratio [HR] = 0.64; 95% CI,
36 al regorafenib 160 mg daily or placebo, plus best supportive care in both groups, for the first 3 wee
37 The panel identified four key domains of best supportive care in clinical trials: multidisciplina
38 vorin, and irinotecan) in study 20050181, or best supportive care in study 20020408 with or without p
39 l survival benefit compared with placebo and best supportive care in the National Cancer Institute of
40 ry 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-acting re
41 edian survival of PS 2 patients treated with best supportive care is 2-3 months, chemotherapy regimen
46 portive care with that of patients receiving best supportive care only in patients with myelodysplast
47 zed trials of anti-EGFR-based therapy versus best supportive care or cytotoxic chemotherapy, no signi
49 emotherapy (P<0.0001) and fewer treated with best supportive care (P=0.0004), mirroring improvements
50 nteractive voice-response system, to receive best supportive care plus either ramucirumab 8 mg/kg or
51 atic disease, and alpha-fetoprotein level to best supportive care plus oral regorafenib 160 mg or pla
52 disease, and geographical region) to receive best supportive care plus oral regorafenib 160 mg or pla
56 mab (8 mg/kg) or placebo every 2 weeks, plus best supportive care, until disease progression, unaccep
57 torical hazard ratio [HR] for cetuximab plus best supportive care vs best supportive care alone of 0.
60 us infusion administered every other week or best supportive care with or without low-dose cytarabine
61 urvival of patients receiving rigosertib and best supportive care with that of patients receiving bes
62 olimus (10 mg per day) or placebo, both with best supportive care, with stratification by tumour orig
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。